Lance-Adams syndrome (LAS) is a chronic neurological sequela secondary to cerebral hypoxic events, characterized by action or intention myoclonus, which can severely impact patient′s quality of life. A case of a 41-year-old male patient with LAS who was initially hospitalized due to trauma was reported in this article. During hospitalization, he experienced airway obstruction leading to respiratory and circulatory disturbance. After successful resuscitation, he developed frequent facial and limb myoclonus, accompanied by dysarthria, dysphagia, and ataxia. The myoclonus was triggered by emotional stress, voluntary movements, or external stimuli. Despite the use of multiple conventional antiseizure medications including valproate (1 g/d), clonazepam (6 mg/d), and levetiracetam (2 g/d), the therapeutic effect remained unsatisfactory. Upon adding the selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist perampanel (initial dose 2 mg/d, increased to 4 mg/d after a week) to the basic treatment regimen, the patient′s myoclonus symptoms significantly improved and he regained independent walking ability after 2 weeks. At the 6-month follow-up, myoclonus remained stably controlled, with the modified Rankin Scale score maintained at 3, indicating sustained improvement in quality of life. This case adds evidence to the clinical practice of treating LAS with perampanel. For LAS patients who respond poorly to conventional medications, perampanel may be an effective treatment option.

Lance-Adams syndrome (LAS) is a chronic neurological sequela secondary to cerebral hypoxic events, characterized by action or intention myoclonus, which can severely impact patient′s quality of life. A case of a 41-year-old male patient with LAS who was initially hospitalized due to trauma was reported in this article. During hospitalization, he experienced airway obstruction leading to respiratory and circulatory disturbance. After successful resuscitation, he developed frequent facial and limb myoclonus, accompanied by dysarthria, dysphagia, and ataxia. The myoclonus was triggered by emotional stress, voluntary movements, or external stimuli. Despite the use of multiple conventional antiseizure medications including valproate (1 g/d), clonazepam (6 mg/d), and levetiracetam (2 g/d), the therapeutic effect remained unsatisfactory. Upon adding the selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist perampanel (initial dose 2 mg/d, increased to 4 mg/d after a week) to the basic treatment regimen, the patient′s myoclonus symptoms significantly improved and he regained independent walking ability after 2 weeks. At the 6-month follow-up, myoclonus remained stably controlled, with the modified Rankin Scale score maintained at 3, indicating sustained improvement in quality of life. This case adds evidence to the clinical practice of treating LAS with perampanel. For LAS patients who respond poorly to conventional medications, perampanel may be an effective treatment option.